Indication intelligence, analysis and sector perception

Opexa (OPXA) P2b Tcelna trial failed to meet endpoints

October 28, 2016 9:10am

OPXA is DOWN -$2.15 to $1.25 at the open after trading halt, OPXA had closed at $3.50 – this failure will reverberate throughout the sector

OPXA plummets 61.76% on HUGE (1.283 M shares) volume in response to its announcement that a P 2b study, Abili-T, assessing Tcelna (imilecleucel-T) in patients with secondary progressive multiple sclerosis failed to meet the primary endpoint of a reduction in brain volume change (atrophy) nor the secondary endpoint of reduction in the rate of sustained disease progression.

OPXA said study of Tcelna in patients with secondary progressive multiple sclerosis didn’t meet primary or secondary endpoints.

OPXA drops -$2.10 to $1.30 after being initially halted; shares had gained 23% YTD through 10/27

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.